Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$1.04 - $322.5 $21,278 - $6.6 Million
-20,460 Reduced 5.94%
323,940 $557,000
Q2 2022

Dec 08, 2022

BUY
$0.41 - $1.24 $141,204 - $427,056
344,400 New
344,400 $427,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Kettle Hill Capital Management, LLC Portfolio

Follow Kettle Hill Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kettle Hill Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kettle Hill Capital Management, LLC with notifications on news.